Production of [211 At]-Astatinated Radiopharmaceuticals and Applications in Targeted alpha-Particle Therapy - Centre de recherche en cancérologie Nantes-Angers Unité Mixte de Recherche 892 Inserm - 6299 CNRS Accéder directement au contenu
Article Dans Une Revue Cancer Biotherapy and Radiopharmaceuticals Année : 2013

Production of [211 At]-Astatinated Radiopharmaceuticals and Applications in Targeted alpha-Particle Therapy

Résumé

211At is a promising radionuclide for a-particle therapy of cancers. Its physical characteristics make this radio-nuclide particularly interesting to consider when bound to cancer-targeting biomolecules for the treatment of microscopic tumors. 211At is produced by cyclotron irradiation of 209 Bi with a-particles accelerated at *28 MeV and can be obtained in high radionuclidic purity after isolation from the target. Its chemistry resembles iodine, but there is also a tendency to behave as a metalloid. However, the chemical behavior of astatine has not yet been clearly established, primarily due to the lack of any stable isotopes of this element, which precludes the use of conventional analytical techniques for its characterization. There are also only a limited number of research centers that have been able to produce this element in sufficient amounts to carry out extensive investigations. Despite these difficulties, chemical reactions typically used with iodine can be performed, and a number of biomolecules of interest have been labeled with 211At. However, most of these compounds exhibit unacceptable instability in vivo due to the weakness of the astatine-biomolecule bond. Nonetheless, several compounds have shown high potential for the treatment of cancers in vitro and in several animal models, thus providing a promising basis that has allowed initiation of the first two clinical studies.
Fichier sous embargo
Fichier sous embargo
Date de visibilité indéterminée
Loading...

Dates et versions

inserm-02496646 , version 1 (03-03-2020)

Identifiants

Citer

François Guérard, Jean-François Gestin, Martin W Brechbiel. Production of [211 At]-Astatinated Radiopharmaceuticals and Applications in Targeted alpha-Particle Therapy. Cancer Biotherapy and Radiopharmaceuticals, 2013, 28 (1), pp.1-20. ⟨10.1089/cbr.2012.1292⟩. ⟨inserm-02496646⟩
68 Consultations
1 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More